Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing

HUNTSVILLE, Ala., Aug. 4 AL-Expression-Genetic


HUNTSVILLE, Ala., Aug. 4 /PRNewswire/ -- Expression Genetics, Inc.,
announced today that it has successfully completed its $12-million Series B
financing. The final portion ($7M) of the financing was secured in July.  The
company plans to use this most recent funding to continue clinical development
of its lead product EGEN-001, a cancer therapeutic, and to further advance its
development of delivery technologies for siRNA and shRNA.


EGEN-001 is under development for the treatment of advanced recurrent
ovarian cancer as well as other local or disseminated solid tumors. The
product is based on proprietary TheraPlas(R) delivery technology. It is
composed of an interleukin-12 (IL-12) gene expression plasmid and a
biocompatible delivery polymer. IL-12 is a potent cytokine which works by
multiple mechanisms of action to enhance the body's immune system against
cancer and inhibit tumor blood supply.  EGEN-001 has completed a Phase I
monotherapy trial with promising results and is currently in the final stage
of a Phase IA trial designed to evaluate safety and preliminary efficacy of
the drug when administered in combination with conventional chemotherapy
treatment. EGEN-001 received Orphan Drug Status from the FDA in 2005 and a $1
million FDA Orphan Grant in 2007.


The company is developing its proprietary TheraSilence(TM) delivery
technology for RNAi therapeutics. Novel molecules, especially designed to
deliver RNAi to cells, are being developed in company laboratories. Gene knock
down in vitro and in vivo in animal models has been demonstrated and candidate
systems targeting specific diseases are being screened for preclinical
development.


"Successful completion of this financing was largely due to recognition
and appreciation of our exciting progress in both the EGEN-001 human clinical
trials and our research advances on RNAi delivery technology. We are pleased
and grateful for this support," commented Dr. Danny H. Lewis, CEO of
Expression Genetics. "This will allow us to expedite the overall clinical
program for EGEN-001 and enable us to continue development of the promising
technologies for delivery of therapeutic RNAi."  Participation in the round
was by VC and private investors.



About Expression Genetics, Inc.


Expression Genetics, Inc. (EGEN), is a privately held biopharmaceutical
company specializing in nucleic acid (DNA and RNAi) delivery and therapeutics
aimed at specific disease targets.  The Company, with laboratories and
headquarters in Huntsville, Alabama, is focused on developing therapeutics for
the treatment of human diseases including cancer and cardiovascular disease.
The Company has a significant intellectual property position in biocompatible
polymers, their novel compositions with nucleic acids, and their therapeutic
applications. EGEN has research pipeline products aimed at treatment of
various cancers and cardiovascular disease involving siRNA, shRNA, tumor
antigens, and angiogenic genes. EGEN has collaborations with outside
investigators, biotech organizations, and universities on various projects in
these areas.



Safe Harbor for Forward Looking Statements


Certain statements contained in this press release may be deemed to be
forward looking statements under federal securities laws and Expression
Genetics intends that such forward looking statements be subject to the safe
harbor created thereby.  Expression Genetics does not undertake an obligation
to publicly update or revise any forward looking statements, whether as a
result of new information, future events or otherwise. Actual events or
results may differ from our expectations as a result of a number of factors,
including but not limited to uncertainties in clinical trials and product
development programs, ability and success level of the Company in securing
adequate capital for operations, market place acceptance of any resulting
product and other factors common to biotechnology research and development.
There can be no guarantee that any product in our pipeline will be
successfully developed.



SOURCE  Expression Genetics, Inc.